SG10202013041QA - The use of spirocyclic compounds as tryptophan hydroxylase inhibitors - Google Patents

The use of spirocyclic compounds as tryptophan hydroxylase inhibitors

Info

Publication number: SG10202013041QA
Authority: SG; Singapore
Prior art keywords: hydroxylase inhibitors; tryptophan hydroxylase; spirocyclic compounds; spirocyclic; compounds
Prior art date: 2013-09-06

Roivant Sciences Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Family has litigation

First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=51743540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202013041Q(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-05Application filed by Roivant Sciences GmbhfiledCriticalRoivant Sciences Gmbh

2021-02-25Publication of SG10202013041QApublicationCriticalpatent/SG10202013041QA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Dispersion Chemistry (AREA)
Physiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

SG10202013041QA2013-09-062014-09-05The use of spirocyclic compounds as tryptophan hydroxylase inhibitorsSG10202013041QA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201361874545P	2013-09-06	2013-09-06
US201361899943P	2013-11-05	2013-11-05
US201462004385P	2014-05-29	2014-05-29

Publications (1)

Publication Number	Publication Date
SG10202013041QAtrue SG10202013041QA (en)	2021-02-25

Family

ID=51743540

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202013041QASG10202013041QA (en)	2013-09-06	2014-09-05	The use of spirocyclic compounds as tryptophan hydroxylase inhibitors
SG10201802118QASG10201802118QA (en)	2013-09-06	2014-09-05	The use of spirocyclic compounds as tryptophan hydroxylase inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201802118QASG10201802118QA (en)	2013-09-06	2014-09-05	The use of spirocyclic compounds as tryptophan hydroxylase inhibitors

Country Status (30)

Country	Link
US (8)	US9199994B2 (en)
EP (1)	EP3041842B8 (en)
JP (1)	JP6470290B2 (en)
KR (1)	KR102336075B1 (en)
CN (1)	CN105764902B (en)
AR (1)	AR097571A1 (en)
AU (1)	AU2014315109B2 (en)
CA (1)	CA2922933C (en)
CL (1)	CL2016000509A1 (en)
CY (1)	CY1122652T1 (en)
DK (1)	DK3041842T3 (en)
EA (1)	EA032304B1 (en)
EC (1)	ECSP16014324A (en)
ES (1)	ES2780828T3 (en)
HR (1)	HRP20200098T1 (en)
HU (1)	HUE047574T2 (en)
IL (1)	IL244315B (en)
LT (1)	LT3041842T (en)
MX (1)	MX371191B (en)
MY (1)	MY186265A (en)
PE (1)	PE20160648A1 (en)
PH (1)	PH12016500416A1 (en)
PL (1)	PL3041842T3 (en)
PT (1)	PT3041842T (en)
RS (1)	RS59871B1 (en)
SG (2)	SG10202013041QA (en)
SI (1)	SI3041842T1 (en)
TW (1)	TWI652267B (en)
UA (1)	UA119247C2 (en)
WO (1)	WO2015035113A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA119247C2 (en)	2013-09-06	2019-05-27	РОЙВЕНТ САЙЕНСИЗ ҐмбГ	Spirocyclic compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en)	2015-03-05	2017-04-04	Karos Pharmaceuticals, Inc.	Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN107176940B (en)*	2016-03-09	2019-05-28	江苏正大丰海制药有限公司	A kind of preparation method for block-regulations woods
WO2018060949A1 (en)*	2016-09-30	2018-04-05	Roivant Sciences Gmbh	Tryptophan hydroxylase inhibitors for use in the treatment of liver diseases
AR110150A1 (en)*	2016-11-09	2019-02-27	Roivant Sciences Gmbh	PROCESSES FOR THE PREPARATION OF TPH1 INHIBITORS
US10472313B1 (en)	2018-02-18	2019-11-12	Graphene 3D Lab Inc.	Process for synthesizing trifluoroketones
CA3119912A1 (en)*	2018-11-14	2020-05-22	Altavant Sciences Gmbh	A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
AU2019382168A1 (en)	2018-11-16	2021-06-03	Altavant Sciences Gmbh	A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128608A1 (en)	2018-12-17	2020-06-25	Altavant Sciences Gmbh	Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US20200188399A1 (en)*	2018-12-17	2020-06-18	Altavant Sciences Gmbh	Method for treating interstitial lung disease
KR20210133953A (en)	2019-01-30	2021-11-08	알타반트 사이언시스 게엠베하	Dosage regimens and methods for the treatment of pulmonary arterial hypertension with rhudatristat ethyl
KR20210139293A (en)*	2019-03-15	2021-11-22	알타반트 사이언시스 게엠베하	Pulmonary Arterial Hypertension and Associated Pulmonary Arterial Hypertension Treatment and Daily Administration
AU2020395766A1 (en)*	2019-12-02	2022-06-16	Onspira Therapeutics, Inc.	Treatment of lower airways disorders
CN111007170B (en)*	2019-12-13	2021-06-29	中国农业科学院农产品加工研究所	Biomarkers, screening methods and uses of osteopeptide in the treatment of osteoporosis
JP2023512025A (en)*	2020-01-31	2023-03-23	アルタバント・サイエンシズ・ゲーエムベーハー	Dosages and Methods for Treating Pulmonary Arterial Hypertension with Rhodatristat
WO2023062595A1 (en)	2021-10-14	2023-04-20	Altavant Sciences Gmbh	Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en)	2021-11-03	2023-05-11	Altavant Sciences Gmbh	Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan
WO2024168165A2 (en)*	2023-02-09	2024-08-15	Geron Corporation	Telomerase inhibitor compounds
WO2025008449A1 (en)	2023-07-05	2025-01-09	Institut National de la Santé et de la Recherche Médicale	Use of tryptophan hydroxylase 1 (tph1) inhibitors for the treatment of atherosclerosis

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1050373A (en)	1989-05-16	1991-04-03	梅迪斯化学药物工厂普特两合股份公司	Preparation optically-active 2-aryl-alkanoic, the particularly method of 2-arylpropionic acid
JP3495376B2 (en)	1996-08-28	2004-02-09	ザプロクターアンドギャンブルカンパニー	Spirocyclic metalloprotease inhibitors
CN1261419C (en)	2000-03-07	2006-06-28	萨诺费－阿文蒂斯德国有限公司	Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
IL162270A0 (en)	2001-12-14	2005-11-20	Novo Nordisk As	Compounds and uses thereof for decreasing activityof hormone-sensitive lipase
DE10247680B4 (en)	2002-10-12	2005-09-01	Aventis Pharma Deutschland Gmbh	New bicyclic inhibitors of the hormone sensitive lipase
MXPA05013224A (en)	2003-06-12	2006-03-09	Novo Nordisk As	Pyridinyl carbamates as hormone-sensitive lipase inhibitors.
EP1636187A1 (en)	2003-06-12	2006-03-22	Novo Nordisk A/S	Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
DE102004005172A1 (en)	2004-02-02	2005-08-18	Aventis Pharma Deutschland Gmbh	Indazole derivatives as inhibitors of the hormone sensitive lipase
DE102005002130A1 (en)	2005-01-17	2006-07-27	Sanofi-Aventis Deutschland Gmbh	New substituted aminomethylene sulfonamides useful as hormone sensitive lipase inhibitors in medicaments for treatment and/or prevention of non-insulin dependent diabetes mellitus, diabetic syndrome or obesity
US8673848B2 (en)	2012-01-27	2014-03-18	Novartis Ag	Synthetic apelin mimetics for the treatment of heart failure
AR057579A1 (en)	2005-11-23	2007-12-05	Merck & Co Inc	SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC)
ES2684821T3 (en)	2005-12-29	2018-10-04	Lexicon Pharmaceuticals, Inc.	Multicyclic amino acid derivatives and methods of their use
UA99270C2 (en)	2006-12-12	2012-08-10	Лексикон Фармасьютикалз, Инк.	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
AU2008216842A1 (en)	2007-02-12	2008-08-21	Merck Sharp & Dohme Corp.	Piperidine derivatives
EP2155734A2 (en)	2007-05-16	2010-02-24	Eli Lilly And Company	Triazolyl aminopyrimidine compounds
CA2693400A1 (en)	2007-07-11	2009-01-15	Lexicon Pharmaceuticals, Inc.	Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2009014972A1 (en)	2007-07-26	2009-01-29	Lexicon Pharmaceuticals, Inc.	Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein
EP2200601A1 (en)	2007-09-24	2010-06-30	Universität Zürich Prorektorat Mnw	Blockers of serotonin and its receptors for the treatment of hepatitis
US8759364B2 (en)	2008-03-31	2014-06-24	The Trustees Of Columbia University In The City Of New York	Methods of treating bone mass diseases
CN104045626B (en)	2008-05-30	2017-01-11	莱西肯医药有限公司	Compounds based on 4-phenyl-6-(2,2,2-trifluoro-1-phenyl ethoxy) pyrimidine and application method thereof
CN101591332B (en)	2008-05-30	2014-04-16	莱西肯医药有限公司	Compounds based on 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine and methods of application thereof
TW201022267A (en)*	2008-10-23	2010-06-16	Gruenenthal Gmbh	Substituierte pyrimidin-und triazin-derivate
US8614222B2 (en)	2008-11-13	2013-12-24	The Trustees Of Columbia University In The City Of New York	Methods of preventing and treating low bone mass diseases
WO2010065333A1 (en)	2008-12-01	2010-06-10	Lexicon Pharmaceuticals, Inc.	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
WO2010109442A1 (en)	2009-03-26	2010-09-30	Ranbaxy Laboratories Limited	Process for the preparation of desloratadine
TW201103540A (en)	2009-06-16	2011-02-01	Ono Pharmaceutical Co	Compound having spiro-linked cyclic group and uses thereof
US8796297B2 (en)	2009-06-30	2014-08-05	Abbvie Inc.	4-substituted-2-amino-pyrimidine derivatives
WO2011053977A1 (en)	2009-11-02	2011-05-05	The Trustees Of Columbia University In The City Of New York	Compounds and methods for inhibiting serotonin synthesis
CA2779681A1 (en)	2009-11-05	2011-05-12	Lexicon Pharmaceuticals, Inc.	Tryptophan hydroxylase inhibitors for the treatment of cancer
WO2011063181A1 (en)	2009-11-23	2011-05-26	Lexicon Pharmaceuticals, Inc.	Methods and assays for the treatment of irritable bowel syndrome
US20130137635A1 (en)	2010-02-10	2013-05-30	Lexicon Pharmaceuticals, Inc.	Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
WO2011103196A1 (en)*	2010-02-17	2011-08-25	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
PE20130404A1 (en)	2010-07-14	2013-04-17	Novartis Ag	AGONISTIC HETEROCYCLIC COMPOUNDS OF THE IP RECEIVER
CN103442568A (en)*	2010-10-08	2013-12-11	Abbvie公司	Furo [3,2-d ] pyrimidine compounds
TW201245183A (en)	2010-11-05	2012-11-16	Lexicon Pharmaceuticals Inc	Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
UY34305A (en)	2011-09-01	2013-04-30	Novartis Ag	DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
WO2013059146A1 (en)	2011-10-17	2013-04-25	Lexicon Pharmaceuticals, Inc.	Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
WO2013074889A1 (en)	2011-11-17	2013-05-23	The Trustees Of Columbia University In The City Of New York	Methods of treating and preventing leukemia and other cancers of the blood and bone
EP2802582A1 (en)	2012-01-13	2014-11-19	Novartis AG	Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105057A1 (en)	2012-01-13	2013-07-18	Novartis Ag	Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
CN104169282B (en)	2012-01-13	2016-04-20	诺华股份有限公司	Salts of IP receptor agonists
EP2802581A1 (en)	2012-01-13	2014-11-19	Novartis AG	7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20150005311A1 (en)	2012-01-13	2015-01-01	Novartis Ag	IP receptor agonist heterocyclic compounds
EP2802585A1 (en)	2012-01-13	2014-11-19	Novartis AG	Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
EP2634190A1 (en)*	2012-03-01	2013-09-04	Lead Discovery Center GmbH	Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
WO2013148978A1 (en)	2012-03-30	2013-10-03	Lexicon Pharmaceuticals, Inc.	Methods and compositions for the treatment of necrotizing enterocolitis
WO2014082034A1 (en)	2012-11-26	2014-05-30	Lexicon Pharmaceuticals, Inc.	Methods for treating irritable bowel syndrome
US9937173B2 (en)	2013-02-15	2018-04-10	Mcmaster University	Method of treating obesity
WO2014195847A2 (en)	2013-06-03	2014-12-11	Actelion Pharmaceuticals Ltd	Novel use of stable isotope labeled l-tryptophan
UA119247C2 (en)*	2013-09-06	2019-05-27	РОЙВЕНТ САЙЕНСИЗ ҐмбГ	Spirocyclic compounds as tryptophan hydroxylase inhibitors
AR098436A1 (en)	2013-11-19	2016-05-26	Actelion Pharmaceuticals Ltd	TRIPYCLIC COMPOUNDS OF PIPERIDINE
TW201609721A (en)	2013-11-19	2016-03-16	艾克泰聯製藥有限公司	Tricyclic imidazole compounds
WO2015089137A1 (en)	2013-12-11	2015-06-18	Karos Pharmaceuticals, Inc.	Acylguanidines as tryptophan hydroxylase inhibitors
EP3061761A1 (en)	2015-02-24	2016-08-31	Max-Delbrück-Centrum für Molekulare Medizin	Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
MA42034A (en)	2015-05-04	2018-03-14	Actelion Pharmaceuticals Ltd	TRICYCLIC PIPERIDINIC COMPOUNDS

2014
- 2014-05-09UAUAA201603580Apatent/UA119247C2/enunknown
- 2014-09-05EPEP14786383.1Apatent/EP3041842B8/enactiveActive
- 2014-09-05JPJP2016540401Apatent/JP6470290B2/enactiveActive
- 2014-09-05PLPL14786383Tpatent/PL3041842T3/enunknown
- 2014-09-05PTPT147863831Tpatent/PT3041842T/enunknown
- 2014-09-05CNCN201480060427.9Apatent/CN105764902B/ennot_activeExpired - Fee Related
- 2014-09-05CACA2922933Apatent/CA2922933C/enactiveActive
- 2014-09-05WOPCT/US2014/054202patent/WO2015035113A1/ennot_activeApplication Discontinuation
- 2014-09-05SGSG10202013041QApatent/SG10202013041QA/enunknown
- 2014-09-05HUHUE14786383Apatent/HUE047574T2/enunknown
- 2014-09-05MYMYPI2016000415Apatent/MY186265A/enunknown
- 2014-09-05MXMX2016002936Apatent/MX371191B/enactiveIP Right Grant
- 2014-09-05SGSG10201802118QApatent/SG10201802118QA/enunknown
- 2014-09-05USUS14/477,948patent/US9199994B2/enactiveActive
- 2014-09-05PEPE2016000340Apatent/PE20160648A1/enunknown
- 2014-09-05AUAU2014315109Apatent/AU2014315109B2/ennot_activeCeased
- 2014-09-05LTLTEP14786383.1Tpatent/LT3041842T/enunknown
- 2014-09-05EAEA201690534Apatent/EA032304B1/ennot_activeIP Right Cessation
- 2014-09-05KRKR1020167009029Apatent/KR102336075B1/ennot_activeExpired - Fee Related
- 2014-09-05TWTW103130893Apatent/TWI652267B/ennot_activeIP Right Cessation
- 2014-09-05SISI201431461Tpatent/SI3041842T1/enunknown
- 2014-09-05HRHRP20200098TTpatent/HRP20200098T1/enunknown
- 2014-09-05RSRS20200059Apatent/RS59871B1/enunknown
- 2014-09-05DKDK14786383.1Tpatent/DK3041842T3/enactive
- 2014-09-05ARARP140103327Apatent/AR097571A1/enactiveIP Right Grant
- 2014-09-05ESES14786383Tpatent/ES2780828T3/enactiveActive
2015
- 2015-09-01USUS14/841,868patent/US9512122B2/ennot_activeExpired - Fee Related
2016
- 2016-02-28ILIL244315Apatent/IL244315B/enactiveIP Right Grant
- 2016-03-03PHPH12016500416Apatent/PH12016500416A1/enunknown
- 2016-03-04CLCL2016000509Apatent/CL2016000509A1/enunknown
- 2016-04-06ECECIEPI201614324Apatent/ECSP16014324A/enunknown
- 2016-09-28USUS15/278,130patent/US9750740B2/ennot_activeExpired - Fee Related
2017
- 2017-07-10USUS15/645,054patent/US10045988B2/enactiveActive
2018
- 2018-05-14USUS15/978,361patent/US10350208B2/enactiveActive
2019
- 2019-05-30USUS16/426,698patent/US10660893B2/enactiveActive
2020
- 2020-01-15CYCY20201100036Tpatent/CY1122652T1/enunknown
- 2020-04-16USUS16/850,542patent/US10946018B2/ennot_activeExpired - Fee Related
2021
- 2021-03-15USUS17/201,750patent/US11759462B2/enactiveActive

Also Published As

Publication number	Publication date
CN105764902A (en)	2016-07-13
HK1225720A1 (en)	2017-09-15
SG10201802118QA (en)	2018-04-27
PT3041842T (en)	2020-02-21
US9750740B2 (en)	2017-09-05
PE20160648A1 (en)	2016-07-09
PL3041842T3 (en)	2020-05-18
US20190282575A1 (en)	2019-09-19
US10045988B2 (en)	2018-08-14
KR20160055190A (en)	2016-05-17
ECSP16014324A (en)	2017-10-31
MX2016002936A (en)	2016-10-07
EP3041842B8 (en)	2019-12-04
CN105764902B (en)	2019-02-15
CY1122652T1 (en)	2021-05-05
US20180256574A1 (en)	2018-09-13
PH12016500416B1 (en)	2016-05-16
HUE047574T2 (en)	2020-05-28
LT3041842T (en)	2020-02-10
ES2780828T3 (en)	2020-08-27
EA201690534A1 (en)	2016-08-31
SI3041842T1 (en)	2020-03-31
US10660893B2 (en)	2020-05-26
AU2014315109A1 (en)	2016-03-17
CA2922933A1 (en)	2015-03-12
IL244315A0 (en)	2016-04-21
AR097571A1 (en)	2016-03-23
US20210205305A1 (en)	2021-07-08
EP3041842A1 (en)	2016-07-13
PH12016500416A1 (en)	2016-05-16
RS59871B1 (en)	2020-03-31
IL244315B (en)	2018-11-29
UA119247C2 (en)	2019-05-27
US20160096836A1 (en)	2016-04-07
MX371191B (en)	2020-01-22
US20170095476A1 (en)	2017-04-06
JP6470290B2 (en)	2019-02-13
HRP20200098T1 (en)	2020-04-03
CA2922933C (en)	2021-08-03
AU2014315109B2 (en)	2018-08-09
US10350208B2 (en)	2019-07-16
DK3041842T3 (en)	2020-01-20
US9512122B2 (en)	2016-12-06
EP3041842B1 (en)	2019-10-23
US10946018B2 (en)	2021-03-16
EA032304B1 (en)	2019-05-31
CL2016000509A1 (en)	2016-08-19
WO2015035113A1 (en)	2015-03-12
KR102336075B1 (en)	2021-12-08
NZ717556A (en)	2021-04-30
JP2016530299A (en)	2016-09-29
BR112016004909A8 (en)	2020-02-11
US20180092918A1 (en)	2018-04-05
US9199994B2 (en)	2015-12-01
US20200237760A1 (en)	2020-07-30
US20150080393A1 (en)	2015-03-19
TWI652267B (en)	2019-03-01
US11759462B2 (en)	2023-09-19
MY186265A (en)	2021-06-30
TW201536785A (en)	2015-10-01

Publication	Publication Date	Title
SG10201802118QA (en)	2018-04-27	The use of spirocyclic compounds as tryptophan hydroxylase inhibitors
IL279682A (en)	2021-03-01	Benzoquinolone inhibitors of vmat2
RS63939B1 (en)	2023-02-28	Inhibitors of lysine specific demethylase-1
IL244609A0 (en)	2016-04-21	4-azaindole derivatives
ZA201604502B (en)	2019-07-31	Use of benzimidazole-proline derivatives
EP2970097A4 (en)	2016-11-16	Methods for the synthesis of chiral kynurenine compounds
ZA201602831B (en)	2017-07-26	Use of lactones
IL244617A0 (en)	2016-04-21	Benzoquinolone inhibitors of vmat2
IL240763B (en)	2019-11-28	Halogenopyrazoles as inhibitors of therombin
IL242847A0 (en)	2016-02-01	Prodrug derivatives of substituted triazolopyridines
IL244411B (en)	2019-10-31	Procedure for the synthesis of n-benzyl-n-cyclopropyl-1h-pyrazole-4-carboxamide derivatives
GB201314965D0 (en)	2013-10-02	Spirocyclic derivatives
GB201314961D0 (en)	2013-10-02	Spirocyclic derivatives
GB201323021D0 (en)	2014-02-12	Use of kinase inhibitors
GB201321227D0 (en)	2014-01-15	Use of kinase inhibitors
GB201309603D0 (en)	2013-07-10	Novel compounds and their use as kinase inhibitors
GB201305741D0 (en)	2013-05-15	Novel compounds and their use as kinase inhibitors

Movatterモバイル変換